J4 ›› 2010, Vol. 36 ›› Issue (6): 1007-1011.

Previous Articles     Next Articles

Construction and identification of double-gene co-expression vector with radiation-inducible human TRAIL and endostatin

LI Yan-Bo1,2, GUO Cai-Xia1,2, GONG Peng-Sheng3, LIU Yang2, LIANG Shuo2, WANG Hong-Fang2, WANG Jian-Feng2, GONG Shou-Liang2   

  1. (1.School of Public Health and Family Medicine,Capital Medical University,Beijing 100069,China;2. Key Laboratory of Radiobiology,Ministry of Health,School of Public Health,Jilin University,Changchun 130021|China;3.Key Laboratory of Molecular Enzymology and Engineering,Ministry of Education,JilinUniversity,Changchun 130023,China)  
  • Received:2010-07-19 Online:2010-11-28 Published:2010-11-28

Abstract:

Abstract:Objective To construct a recombinant plasmid pshuttle-Egr1-shTRAIL-shES containing tumor necrosis factor-related apoptosis-inducing ligand(TRAIL) and endostatin double genes.Methods The secretary endostatin gene (shES) fragment was amplified from the pMD19T-endostatin vector by PCR. The shES gene was ligated to pMD19T and sequenced. Finally,using the gene recombinant technique,the recombinant plasmid pshuttle-Egr1-shTRAIL-shES with radiation-inducible Egr1 promoter,secretary TRAIL and endostatin double-gene was constructed.  Results The sequence of the shES gene was in concordance with that anticipated indicating shES gene was acquired successfully. Moreover,the results acquired by PCR and restrictive digestion identification of the recombinant plasmid pshuttle-Egr1-shTRAIL-shES and all the vectors refered to its construction confirmed that pshuttle-Egr1-shTRAIL-shES was constructed correctly. Conclusion The radiation-inducible double-gene co-expression vector pshuttle-Egr1-shTRAIL-shES is constructed successfully,which would set the experimental foundation for further study on the anti-tumor effect of TRAIL and endostatin double-gene-radiotherapy and its related mechanisms.

Key words: umor necrosis factor-related apoptosis-inducing ligand;endostatin;radiation;Egr1 promoter

CLC Number: 

  • Q691